Brisbane biotech Vaxxas secures US patent for needle-free vaccine technology

Brisbane-based clinical-stage biotechnology company Vaxxas secured a new patent from the United States patent office covering its proprietary manufacturing technology for needle-free vaccine patches, the company announced on Wednesday. The patent covers Vaxxas’ printhead system that dispenses dried vaccine formulations onto the company’s high-density microarray patch (HD-MAP), which features thousands of microscopic projections on a…

Can the Strategic Examination of R&D solve 2025’s innovation challenges?

By John H Howard The Strategic Examination of Research and Development (SERD) has been established to report on how a more strategic approach to R&D can boost economic growth and productivity. Expressly, SERD has been requested to examine the optimisation of existing R&D investments across all sectors and how to strengthen research-industry connections, support national priorities…

Towards 3% R&D – patent box still missing from innovation system by BDO

Today in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Daniel Splatt and Michelle Tan highlight the benefits of a patent box system, much advocated but missing from our innovation ecosystem. The World Intellectual Property Organisation’s Global Innovation Index has revealed a steady decline in Australia’s knowledge, technology, and creative…

UQ expertise bolsters aluminium ion battery tech

The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology is to work with Graphene Manufacturing Group in its quest to commercialise novel Graphene Aluminium-Ion Battery Technology. The development, supported by the federal government’s Economic Accelerator Seed Grant, will accelerate under a partnership between AIBN material chemist Dr Xiaodan Huang (pictured, below) and GMG’s supporting…